Tirzepatide and change in uric acid and its association with weight reduction: post hoc analyses of the SURMOUNT-1 randomised placebo-controlled trial
In this post hoc analysis, in participants with obesity or overweight, tirzepatide was associated with meaningfully reduced SUA levels, regardless of participants' baseline BMI or SUA levels, and appeared to be so primarily via weight reduction. These findings warrant further investigation into the possible role that tirzepatide/intentional weight loss may play in the treatment of patients with gout living with obesity.
Authors
- Sabrina Scilletta (ORCID: https://orcid.org/0009-0001-9061-0368)
- Naveed A. Sattar (ORCID: https://orcid.org/0000-0002-1604-2593)
- Bruno Linetzky (ORCID: https://orcid.org/0009-0009-4015-7794)
- Hui Wang (ORCID: https://orcid.org/0000-0003-0141-4865)
- John Daly (ORCID: https://orcid.org/0000-0002-8017-2974)
- Adam Stefański (ORCID: https://orcid.org/0009-0001-7598-402X)
Institutions
- Eli Lilly (United States) (US)
- University of Catania (IT)
- University of Glasgow (GB)
Publication Details
- Journal
- Annals of the Rheumatic Diseases
- Published
- 2025-11-06
- DOI
- https://doi.org/10.1016/j.ard.2025.10.009
- Citations
- 1
- Primary Topic
- Gout, Hyperuricemia, Uric Acid
- Type
- article
- Field-Weighted Citation Impact
- 1.43